Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roelofs, R. I.
Right arrow Articles by Rosenberg, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roelofs, R. I.
Right arrow Articles by Rosenberg, L.
NEUROLOGY 1984;34:934
© 1984 American Academy of Neurology

Peripheral sensory neuropathy and cisplatin chemotherapy

Robert I. Roelofs, MD, William Hrushesky, MD, Joanne Rogin, MD and Leon Rosenberg, MD

From the Departments of Neurology (Drs. Roelofs, Rogin, and Rosenberg) and Internal Medicine (Dr. Hrushesky), University of Minnesota Medical School, Minneapolis, MN.

Patients with advanced cancer, previously untreated, were given 60 mg/m2 cisplatin plus 60 mg/m2 adriamycin by monthly intravenous injections. Signs and symptoms of a predominantly sensory peripheral neuropathy developed in 92% of the patients. Patients complained of dysesthesias and paresthesias in hands and feet. Clinically, there was progressive decrease or loss of tendon reflexes, decreased vibratory sense, and mild decrease in light touch and pin sensation. Distal sensory latencies became prolonged or dropped out completely, but there was little change in motor nerve conduction velocities or motor unit action potentials. Sural nerve biopsies showed loss of large-diameter nerve fibers, with axonal and myelin degeneration.

Address correspondence and reprint requests to Dr. Roelofs, the Department of Neurology, University of Minnesota Medical School, Minneapolis, MN 55455.

Supported in part by NIH grant No. R01-CA-31635-01, NIH grant No. 5M-01RR00400, American Cancer Society Junior Faculty Fellowship No. 509, Masonic Memorial Hospital Fund Inc., and a private donation from Dr. Harold Lawn.

Presented in part at the thirty-fourth annual meeting of the American Academy of Neurology, Washington, DC, April 1982.

Accepted for publication November 11, 1983.




This article has been cited by other articles:


Home page
 Journals of Gerontology Series B: Psychological Sciences and Social ScienceHome page
J. M. Duchek, D. A. Balota, M. Storandt, and R. Larsen
The Power of Personality in Discriminating Between Healthy Aging and Early-Stage Alzheimer's Disease
J. Gerontol. B. Psychol. Sci. Soc. Sci., November 1, 2007; 62(6): P353 - P361.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. Krarup-Hansen, S. Helweg-Larsen, H. Schmalbruch, M. Rorth, and C. Krarup
Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies
Brain, April 1, 2007; 130(4): 1076 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Strumberg, S. Brugge, M. W. Korn, S. Koeppen, J. Ranft, G. Scheiber, C. Reiners, C. Mockel, S. Seeber, and M. E. Scheulen
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer
Ann. Onc., February 20, 2002; 13(2): 229 - 236.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M SANCHEZ-GUERRA, O COMBARROS, A ALVAREZ-ARCAYA, I MATEO, J BERCIANO, J GONZALEZ-GARCIA, and J LLORCA
The Glu298Asp polymorphism in the NOS3 gene is not associated with sporadic Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, April 1, 2001; 70(4): 566 - 567.
[Full Text]

Home page
 NeurologyHome page
O. Combarros, M. Sanchez-Guerra, J. Llorca, A. Alvarez-Arcaya, J. Berciano, N. Pena, and C. Fernandez-Viadero
Polymorphism at codon 129 of the prion protein gene is not associated with sporadic AD
Neurology, August 22, 2000; 55(4): 593 - 595.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
S. Poser, B. Mollenhauer, A. Krau{beta}, I. Zerr, B. J. Steinhoff, A. Schroeter, M. Finkenstaedt, W. J. Schulz-Schaeffer, H. A. Kretzschmar, and K. Felgenhauer
How to improve the clinical diagnosis of Creutzfeldt-Jakob disease
Brain, December 1, 1999; 122(12): 2345 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Devi, R. Ottman, M. Tang, K. Marder, Y. Stern, B. Tycko, and R. Mayeux
Influence of APOE genotype on familial aggregation of AD in an urban population
Neurology, September 1, 1999; 53(4): 789 - 789.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Alberts and R. T. Dorr
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
Oncologist, February 1, 1998; 3(1): 15 - 34.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
C. M. Filley, R. K. Heaton, L. M. Nelson, J. S. Burks, and G. M. Franklin
A Comparison of Dementia in Alzheimer's Disease and Multiple Sclerosis
Arch Neurol, February 1, 1989; 46(2): 157 - 161.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
K. Urakami, Y. Adachi, and K. Takahashi
A Community-Based Study of Parental Age at the Birth of Patients With Dementia of the Alzheimer Type
Arch Neurol, January 1, 1989; 46(1): 38 - 39.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
C. M. BAGLEY JR., R. H. RUDOLPH, S. E. RIVKIN, and J. L. YON JR.
High-Dose Cisplatin Therapy for Cancer for the Ovary: Neurotoxicity
Ann Intern Med, May 1, 1985; 102(5): 719 - 719.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by AAN Enterprises, Inc.